Table 2.
Prevalence of comorbidities in the study cohorts prior to index date
| Comorbiditya | Main cohort | Treated cohort | Data lake cohort |
|---|---|---|---|
| (n = 2037) | (n = 1615) | (n = 551) | |
| Charlson comorbidity index | |||
| 0 | 1018 (50.0) | 861 (53.3) | 323 (58.6) |
| 1 | 329 (16.2) | 238 (14.7) | 75 (13.6) |
| 2 | 203 (10.0) | 152 (9.4) | 48 (8.7) |
| ≥ 3 | 487 (23.9) | 364 (22.5) | 105 (19.1) |
| Diseases of circulatory system | 1165 (57.2) | 870 (53.9) | 274 (49.7) |
| Elevated blood pressure | 890 (43.7) | 659 (40.8) | 217 (39.4) |
| Congestive heart failure | 199 (9.8) | 126 (7.8) | 24 (4.4) |
| Atrial fibrillation | 303 (14.9) | 206 (12.8) | 50 (9.1) |
| Ischemic heart disease | 248 (12.2) | 174 (10.8) | 31 (5.6) |
| Cerebrovascular disease | 148 (7.3) | 110 (6.8) | 28 (5.1) |
| Peripherial arterial disease | 83 (4.1) | 55 (3.4) | 13 (2.4) |
| Dementia | 77 (3.8) | 44 (2.7) | 6 (1.1) |
| Parkinson’s disease | 16 (0.8) | 9 (0.6) | < 5 |
| Other cancers, excl. non-melanoma skin cancer | 281 (13.8) | 209 (12.9) | 60 (10.9) |
| Moderate to severe renal disease | 185 (9.1) | 142 (8.8) | 42 (7.6) |
| Moderate to severe liver disease | 6 (0.3) | < 5 | 0 (0.0) |
| Any neuropathy | 31 (1.5) | 20 (1.2) | < 5 |
| Amyloidosis | 23 (1.1) | 19 (1.2) | < 5 |
a Identified from Hilmo and/or AvoHilmo within 4 years prior to the index date. Numbers are frequencies (percentages)